

10/560260

Attorney Docket No.: 10328.204-US

IAP13 Rec'd PCT/PTO 09 PATENT  
DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Segura et al Confirmation No: TBA

Serial No.: To be assigned Group Art Unit: TBA

Filed: December 9, 2005 Examiner: TBA

For: Antimicrobial Peptides

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed. It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,



Gabriela Materassi, Reg. No. 47,774  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

Date: December 9, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				<p>Complete if Known: 1540260</p> <p>To be assigned</p>	
				Application Number	To be assigned
				Filing Date	December 9, 2005
				First Named Inventor	Segura et al
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	2	Attorney Docket Number	10328.204-US

## **U.S PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)</p>				<p><b>Complete if Known</b></p> <table border="1"> <tr> <td><b>Application Number</b></td> <td>To be assigned 0268</td> </tr> <tr> <td><b>Filing Date</b></td> <td>December 9, 2005</td> </tr> <tr> <td><b>First Named Inventor</b></td> <td>Segura et al</td> </tr> <tr> <td><b>Art Unit</b></td> <td>TBA</td> </tr> <tr> <td><b>Examiner Name</b></td> <td>TBA</td> </tr> <tr> <td><b>Attorney Docket Number</b></td> <td>10328.204-US</td> </tr> </table>		<b>Application Number</b>	To be assigned 0268	<b>Filing Date</b>	December 9, 2005	<b>First Named Inventor</b>	Segura et al	<b>Art Unit</b>	TBA	<b>Examiner Name</b>	TBA	<b>Attorney Docket Number</b>	10328.204-US
<b>Application Number</b>	To be assigned 0268																
<b>Filing Date</b>	December 9, 2005																
<b>First Named Inventor</b>	Segura et al																
<b>Art Unit</b>	TBA																
<b>Examiner Name</b>	TBA																
<b>Attorney Docket Number</b>	10328.204-US																
Sheet	2	of	2														

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.